Paola Queirolo, Former Director of the Melanoma, Sarcoma and Rare Tumors Division at IEO, shared a post on LinkedIn about a paper she co-authored with colleagues published in the British Journal of Cancer:
“New publication in the British Journal of Cancer
I’m happy to share the results of our latest systematic review and meta-analysis on the role of sex and gender in treatment-related adverse events among melanoma patients, with Dr. Sara Gandini and me serving as senior authors.
Analyzing data from 69 studies, we found that:
- Women have a significantly higher risk of thyroid-related adverse events during immunotherapy and targeted therapy
- No major sex/gender differences emerged for most other toxicities
- These findings highlight the importance of a more tailored and attentive monitoring, particularly for women receiving first-line treatments
As melanoma therapies continue to evolve, understanding sex- and gender-based differences is key to improving treatment safety and adherence.
British Journal of Cancer, 2025.”
Title: Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis
Authors: Aurora Gaeta, Luca Nuvoli, Chiara Doccioli, Saverio Caini, Maristella Saponara, Carolina Cimminiello, Claudia Cosma, Giuseppe Palmieri, Antonio Cossu, Francesco Vicini, Luca Mazzarella, Giulio Tosti, Paola Queirolo, Sara Gandini
You can read the Full Article in the British Journal of Cancer.
More posts featuring Paola Queirolo.